.: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies."
.
.
.
.
.
.
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.